Defendant
3 cases as defendant.
Neurent Medical Ltd is a privately held MedTech company headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts. Founded in 2015 by David Townley and Brian Shields, the company employs approximately 35 to 76 individuals and is venture-backed. Neurent Medical has raised substantial funding, including a €62.5 million ($74 million) Series C financing round in February 2026.
The company specializes in developing innovative treatments for chronic inflammatory sino-nasal diseases. Its primary product is the NEUROMARK® System, a minimally invasive device that utilizes proprietary Impedance Controlled Radiofrequency technology. This system is designed to precisely target and disrupt hyperactive posterior nasal nerves, providing relief from chronic rhinitis symptoms such as congestion, rhinorrhea, sneezing, and nasal itching. The NEUROMARK® System has received U.S. FDA clearance for its next-generation device and has a dedicated CPT code for reimbursement.
Neurent Medical demonstrates an active two-way patent litigation posture. The company has appeared as a plaintiff in one tracked case, Neurent Medical Ltd. v. Aerin Medical Inc. in the U.S. District Court for the District of Delaware, filed in September 2024. Simultaneously, it has been a defendant in one case, Unified Patents v. Neurent Medical Ltd, before the Patent Trial and Appeal Board (PTAB). This indicates that Neurent Medical is both asserting its patent rights and defending them against challenges.
Aerin appeals the PTAB's Final Written Decision in IPR2024-00282 invalidating all challenged claims of the '286 patent. The appeal is pending and consolidated with 25-2099 and 25-2100; no docket entries after October 23, 2025 were available.
Aerin and The Foundry asserted eight patents, including the '077 patent, against Neurent's NEUROMARK nasal-airway treatment device. The case was stayed after PTAB instituted IPR2024-00669 and was consolidated with related matters; counterclaims and motions to dismiss were pending.
Aerin and Foundry sued Neurent in Delaware alleging infringement of eight patents, including the '286 patent, by Neurent's NEUROMARK System. The case was stayed pending IPR final written decisions; after the PTAB invalidated the '286 claims and Aerin appealed, the current docket posture was unconfirmed.